Takeda oncology pipeline shifts in focus

23 February 2024
takeda_corporate_large

Japan’s largest drugmaker Takeda (TYO: 4502) decided to discontinue the development programs of its four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing allogeneic cell therapies.

Despite these adjustments, the Japan-based pharma major's oncology pipeline remains robust, says pharma analytics company GlobalData.

Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organizations like Memorial Sloan Kettering Cancer Center (MSK), Noile-Immune Biotech, and Crescendo Biologics in 2019 to advance the company’s novel immuno-oncology portfolio. Subsequently, the company had established a cell therapy manufacturing facility in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology